title: Left ventricular thrombus formation and bleeding complications during continuous in-hospital anticoagulation for acute anterior myocardial infarction.
abstract: BACKGROUND
  The 20%-60% rate of acute anterior myocardial infarction (AAMI) patients with concomitant left ventricular thrombus (LVT) formation dropped to 10-20% when thrombolysis and primary percutaneous coronary intervention (PPCI) were introduced.
  
  
  OBJECTIVE
  To test our hypothesis that prolonged anticoagulation post-PPCI will lower the LVT incidence even further.
  
  
  METHODS
  Included in this study were all 296 inpatients with ST elevation AAMI who were treated with PPCI (from January 2006 to December 2009). Treatment included heparin anticoagulation (48 hours) followed by adjusted doses of low molecular weight heparin (3 more days). All patients underwent cardiac echocardiography on admission and at discharge. LVT and bleeding complications were reviewed and compared.
  
  
  RESULTS
  LVT formation was present on the first echocardiogram in 6/296 patients. Another 8/289 patients displayed LVT only on their second echocardiogram (4.7%, 14/296). LVT patients had significantly lower LV ejection fractions than non-LVT patients at admission (P < 0.003) and at discharge (P < 0.001), and longer time to reperfusion (P = 0.168). All patients were epidemiologically and clinically similar. There were 6 bleeding episodes that required blood transfusion and 11 episodes of minor bleeding.
  
  
  CONCLUSIONS
  Five days of continuous anticoagulation therapy post-PPCI in inpatients with AAMI is associated with low LVT occurrence without remarkably increasing bleeding events.
authors: Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. kobyshacham@gmail.com
authors: Yacov
authors: Y
authors: Shacham
authors: Edo Y
authors: EY
authors: Birati
authors: Ori
authors: O
authors: Rogovski
authors: Yevgeni
authors: Y
authors: Cogan
authors: Gad
authors: G
authors: Keren
authors: Arie
authors: A
authors: Roth
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000175:diagnosis / Q000209:etiology*; D006352:Heart Ventricles; D006470:Hemorrhage / Q000139:chemically induced* / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D062645:Percutaneous Coronary Intervention; D012189:Retrospective Studies; D013927:Thrombosis / Q000175:diagnosis / Q000209:etiology*
chemical_list: D000925:Anticoagulants